SitemapContact Us
닫기
Search
Advanced Search +
닫기
Quick links
Most Cited Most Read Ahead of Print Archives Go to E-submission

Review Article

Split Viewer

Blood Res 2022; 57(1):

Published online March 31, 2022

https://doi.org/10.5045/br.2022.2022043

© The Korean Society of Hematology

Management of immune thrombocytopenia: 2022 update of Korean experts recommendations

Young Hoon Park1#, Dae-Young Kim2#, Seongkoo Kim3, Young Bae Choi4, Dong-Yeop Shin5, Jin Seok Kim6, Won Sik Lee7, Yeung-Chul Mun1, Jun Ho Jang8, Jong Wook Lee9, Hoon Kook10, on behalf of Korean Aplastic Anemia Working Party

Author Info. +

1Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, 2Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji Univerisity, 3Department of Pediatrics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 4Department of Pediatrics, Ajou University School of Medicine, Ajou Univeristy Hospital, Suwon, 5Department of Internal Medicine, Seoul National University Hospital, 6Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, 7Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, 8Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 9Department of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 10Department of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun, Korea

Correspondence to : Jun Ho Jang, M.D., Ph.D.
Yeung-Chul Mun, M.D., Ph.D.
Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Korea (J.H.J.)
Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, 1071, Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea (Y.C.M.)
E-mail: J.H.J., smcjunhojang@gmail.com
Y.C.M., yeungchul@ewha.ac.kr
#These authors contributed equally to this work.

Received: February 18, 2022; Revised: March 11, 2022; Accepted: March 14, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Go to

Despite the availability of therapies to treat patients with immune thrombocytopenia (ITP), there is currently little data from randomized trials to assist clinicians in managing patients. The evidence-based guidelines of the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) are intended to support patients and physicians in the management of ITP. Experts from the KSHAAWP discussed and described this guideline according to the current treatment situation for ITP in Korea and finalized the guidelines. The expert panel recommended the management of ITP in adult and pediatric patients with newly diagnosed, persistent, and chronic disease refractory to first-line therapy with minor bleeding. Management approaches include observation and administration of corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, and thrombopoietin receptor agonists. Currently, evidence supporting strong recommendations for various management approaches is lacking. Therefore, a large focus was placed on shared decision-making, especially regarding second-line treatment.

Keywords Immune thrombocytopenia, Recommendation, Management

Article

Review Article

Blood Res 2022; 57(1): 20-28

Published online March 31, 2022 https://doi.org/10.5045/br.2022.2022043

Copyright © The Korean Society of Hematology.

Management of immune thrombocytopenia: 2022 update of Korean experts recommendations

Young Hoon Park1#, Dae-Young Kim2#, Seongkoo Kim3, Young Bae Choi4, Dong-Yeop Shin5, Jin Seok Kim6, Won Sik Lee7, Yeung-Chul Mun1, Jun Ho Jang8, Jong Wook Lee9, Hoon Kook10, on behalf of Korean Aplastic Anemia Working Party

1Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, 2Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji Univerisity, 3Department of Pediatrics, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 4Department of Pediatrics, Ajou University School of Medicine, Ajou Univeristy Hospital, Suwon, 5Department of Internal Medicine, Seoul National University Hospital, 6Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, 7Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, 8Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 9Department of Hematology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 10Department of Pediatrics, Chonnam National University Hwasun Hospital, Hwasun, Korea

Correspondence to:Jun Ho Jang, M.D., Ph.D.
Yeung-Chul Mun, M.D., Ph.D.
Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Korea (J.H.J.)
Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University Mokdong Hospital, 1071, Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea (Y.C.M.)
E-mail: J.H.J., smcjunhojang@gmail.com
Y.C.M., yeungchul@ewha.ac.kr
#These authors contributed equally to this work.

Received: February 18, 2022; Revised: March 11, 2022; Accepted: March 14, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Despite the availability of therapies to treat patients with immune thrombocytopenia (ITP), there is currently little data from randomized trials to assist clinicians in managing patients. The evidence-based guidelines of the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) are intended to support patients and physicians in the management of ITP. Experts from the KSHAAWP discussed and described this guideline according to the current treatment situation for ITP in Korea and finalized the guidelines. The expert panel recommended the management of ITP in adult and pediatric patients with newly diagnosed, persistent, and chronic disease refractory to first-line therapy with minor bleeding. Management approaches include observation and administration of corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, and thrombopoietin receptor agonists. Currently, evidence supporting strong recommendations for various management approaches is lacking. Therefore, a large focus was placed on shared decision-making, especially regarding second-line treatment.

Keywords: Immune thrombocytopenia, Recommendation, Management

Fig 1.

Download
Figure 1.Algorithm for the selection of second-line therapy in adult patients with ITP.
Blood Research 2022; 57: 20-28https://doi.org/10.5045/br.2022.2022043
Blood Res
Volume 59 2024
Current Issue Archives

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download